Skip to main content
Erschienen in: Medical Oncology 4/2012

01.12.2012 | Original Paper

Overexpression of EphA2 correlates with epithelial–mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients

verfasst von: Futao Hou, Weijie Yuan, Jin Huang, Liyuan Qian, Zhikang Chen, Jie Ge, Shaobin Wu, Jinxiang Chen, Jixu Wang, Zihua Chen

Erschienen in: Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The expression of EphA2 and three epithelial–mesenchymal transition-related proteins (E-cadherin, β-catenin and vimentin) was detected by immunohistochemistry in human gastric cancer and normal gastric mucosa. The expression of EphA2 and vimentin was significantly higher in gastric cancer tissues than in normal gastric mucosa tissues, and similar results were found for negative E-cadherin expression and ectopic β-catenin expression. Further analysis showed that the expression of EphA2 was closely correlated with the depth of tumor invasion, tumor–node–metastasis (TNM) stages and lymph node metastasis. Down-regulated expression of the epithelial protein E-cadherin, overexpression of the mesenchymal protein vimentin and ectopic expression of β-catenin were associated with the depth of tumor invasion, tumor differentiation, TNM stages and lymph node metastasis. The Spearman rank test indicated that the positive expression of EphA2 was negatively associated with E-cadherin expression and was positively correlated with β-catenin ectopic expression and vimentin expression. In addition, the Kaplan–Meier survival analysis showed that the overexpression of EphA2 and vimentin, ectopic expression of β-catenin and down-regulation of E-cadherin indicate a poor outcome. Moreover, multivariate Cox analysis showed that TNM stages, lymph node metastasis, EphA2 expression, E-cadherin expression and β-catenin ectopic expression were independent prognostic factors for postoperative gastric cancer. These findings indicate that the overexpression of EphA2 correlates with the loss of epithelial proteins and the appearance of mesenchymal proteins. Therefore, EphA2 may play a role in epithelial–mesenchymal transition in gastric cancer.
Literatur
2.
Zurück zum Zitat Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27–39.PubMed Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27–39.PubMed
3.
Zurück zum Zitat Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001;61:3250–5.PubMed Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001;61:3250–5.PubMed
4.
Zurück zum Zitat Ireton RC. Chen J: EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets. 2005;5:149–57.PubMedCrossRef Ireton RC. Chen J: EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets. 2005;5:149–57.PubMedCrossRef
5.
Zurück zum Zitat Lu C, Shahzad MM, Wang H, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008;7:1098–103.PubMedCrossRef Lu C, Shahzad MM, Wang H, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008;7:1098–103.PubMedCrossRef
6.
Zurück zum Zitat Yuan W, Chen Z, Wu S, et al. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res. 2009;15:473–8.PubMedCrossRef Yuan W, Chen Z, Wu S, et al. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res. 2009;15:473–8.PubMedCrossRef
7.
Zurück zum Zitat Thiery JP, Acloque H, Huang RY, et al. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139:871–90.PubMedCrossRef Thiery JP, Acloque H, Huang RY, et al. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139:871–90.PubMedCrossRef
8.
Zurück zum Zitat Micalizzi DS, Farabaugh SM, Ford HL. Epithelial–mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.PubMedCrossRef Micalizzi DS, Farabaugh SM, Ford HL. Epithelial–mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.PubMedCrossRef
9.
Zurück zum Zitat Tomita K, van Bokhoven A, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000;60:3650–4.PubMed Tomita K, van Bokhoven A, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000;60:3650–4.PubMed
10.
Zurück zum Zitat Schmalhofer O, Brabletz S, Brabletz T. E-cadherin beta-catenin and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66.PubMedCrossRef Schmalhofer O, Brabletz S, Brabletz T. E-cadherin beta-catenin and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66.PubMedCrossRef
11.
Zurück zum Zitat Benjamin JM, Kwiatkowski AV, Yang C, et al. AlphaE-catenin regulates actin dynamics independently of cadherin-mediated cell–cell adhesion. J Cell Biol. 2010;189:339–52.PubMedCrossRef Benjamin JM, Kwiatkowski AV, Yang C, et al. AlphaE-catenin regulates actin dynamics independently of cadherin-mediated cell–cell adhesion. J Cell Biol. 2010;189:339–52.PubMedCrossRef
12.
Zurück zum Zitat Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.PubMedCrossRef Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.PubMedCrossRef
13.
Zurück zum Zitat Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–58.PubMedCrossRef Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–58.PubMedCrossRef
14.
Zurück zum Zitat Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145–50.PubMedCrossRef Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145–50.PubMedCrossRef
15.
Zurück zum Zitat Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007;109:332–40.PubMedCrossRef Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007;109:332–40.PubMedCrossRef
16.
Zurück zum Zitat Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997;112:46–54.PubMedCrossRef Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997;112:46–54.PubMedCrossRef
17.
Zurück zum Zitat Zhou Y, Ran J, Tang C. Effect of celecoxib on E-cadherin, VEGF. Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther. 2007;6:269–75.PubMed Zhou Y, Ran J, Tang C. Effect of celecoxib on E-cadherin, VEGF. Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther. 2007;6:269–75.PubMed
18.
Zurück zum Zitat Prudkin L, Liu DD, Ozburn NC, et al. Epithelial–mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22:668–78.PubMedCrossRef Prudkin L, Liu DD, Ozburn NC, et al. Epithelial–mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22:668–78.PubMedCrossRef
19.
Zurück zum Zitat Yang P, Yuan W, He J, et al. Overexpression of EphA2, MMP-9 and MVD-CD34 in hepatocellular carcinoma: implications for tumor progression and prognosis. Heptol Res. 2009;39:1169–77.CrossRef Yang P, Yuan W, He J, et al. Overexpression of EphA2, MMP-9 and MVD-CD34 in hepatocellular carcinoma: implications for tumor progression and prognosis. Heptol Res. 2009;39:1169–77.CrossRef
20.
Zurück zum Zitat Cui XD, Lee MJ, Yu GR, et al. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer. 2010;126:940–9.PubMed Cui XD, Lee MJ, Yu GR, et al. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer. 2010;126:940–9.PubMed
21.
Zurück zum Zitat Brannan JM, Dong W, Prudkin L, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009;15:4423–30.PubMedCrossRef Brannan JM, Dong W, Prudkin L, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009;15:4423–30.PubMedCrossRef
22.
Zurück zum Zitat Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep. 2008;19:151–6.PubMed Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep. 2008;19:151–6.PubMed
23.
Zurück zum Zitat Kamat AA, Coffey D, Merritt WM, et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009;115:2684–92.PubMedCrossRef Kamat AA, Coffey D, Merritt WM, et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009;115:2684–92.PubMedCrossRef
24.
Zurück zum Zitat Merrit WM, Thaker PH, Landen CN Jr, et al. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther. 2006;5:1357–60.CrossRef Merrit WM, Thaker PH, Landen CN Jr, et al. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther. 2006;5:1357–60.CrossRef
25.
Zurück zum Zitat Kataoka H, Igarashi H, Kanamori M, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004;95:136–41.PubMedCrossRef Kataoka H, Igarashi H, Kanamori M, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004;95:136–41.PubMedCrossRef
26.
Zurück zum Zitat Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305–18.PubMedCrossRef Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305–18.PubMedCrossRef
27.
Zurück zum Zitat Thiery JP. Epithelial-mesenchymal transition in tumor progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRef Thiery JP. Epithelial-mesenchymal transition in tumor progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRef
28.
Zurück zum Zitat Nieto MA. Epithelial–mesenchymal transitions in development and disease: old views and new perspectives. Int J Dev Biol. 2009;53:1541–7.PubMedCrossRef Nieto MA. Epithelial–mesenchymal transitions in development and disease: old views and new perspectives. Int J Dev Biol. 2009;53:1541–7.PubMedCrossRef
29.
Zurück zum Zitat Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33.PubMedCrossRef Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33.PubMedCrossRef
30.
Zurück zum Zitat Almeida PR, Ferreira VA, Santos CC, et al. E-cadherin immunoexpression patterns in the characterisation of gastric carcinoma histotypes. J Clin Pathol. 2010;63:635–9.PubMedCrossRef Almeida PR, Ferreira VA, Santos CC, et al. E-cadherin immunoexpression patterns in the characterisation of gastric carcinoma histotypes. J Clin Pathol. 2010;63:635–9.PubMedCrossRef
31.
Zurück zum Zitat Zhou Y, Li G, Wu J, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol. 2010;31:549–58.PubMedCrossRef Zhou Y, Li G, Wu J, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol. 2010;31:549–58.PubMedCrossRef
32.
Zurück zum Zitat Guarino M, Rubino B, Ballabio G. The role of epithelial–mesenchymal transition in cancer pathology. Pathology. 2007;39:305–18.PubMedCrossRef Guarino M, Rubino B, Ballabio G. The role of epithelial–mesenchymal transition in cancer pathology. Pathology. 2007;39:305–18.PubMedCrossRef
33.
Zurück zum Zitat MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.PubMedCrossRef MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.PubMedCrossRef
34.
Zurück zum Zitat Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–47.PubMedCrossRef Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–47.PubMedCrossRef
35.
Zurück zum Zitat Song S, Mazurek N, Liu C, et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009;69:1343–9.PubMedCrossRef Song S, Mazurek N, Liu C, et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009;69:1343–9.PubMedCrossRef
36.
Zurück zum Zitat Fukuyama R, Niculaita R, Ng KP, et al. Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene. 2008;27:6044–55.PubMedCrossRef Fukuyama R, Niculaita R, Ng KP, et al. Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene. 2008;27:6044–55.PubMedCrossRef
37.
Zurück zum Zitat Lovatt M, Bijlmakers MJ. Stabilisation of β-catenin downstream of T cell receptor signaling. PLoS One. 2010;5:e12794.PubMedCrossRef Lovatt M, Bijlmakers MJ. Stabilisation of β-catenin downstream of T cell receptor signaling. PLoS One. 2010;5:e12794.PubMedCrossRef
38.
Zurück zum Zitat Wang Q, Sun ZX, Allgayer H, et al. Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene. 2010;29:128–38.PubMedCrossRef Wang Q, Sun ZX, Allgayer H, et al. Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene. 2010;29:128–38.PubMedCrossRef
39.
Zurück zum Zitat Miyazawa K, Iwaya K, Kroda M, et al. Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. Virchows Arch. 2000;437:508–13.PubMedCrossRef Miyazawa K, Iwaya K, Kroda M, et al. Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. Virchows Arch. 2000;437:508–13.PubMedCrossRef
40.
Zurück zum Zitat Zhou YN, Xu CP, Han B, et al. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 2002;8:987–93.PubMed Zhou YN, Xu CP, Han B, et al. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 2002;8:987–93.PubMed
41.
Zurück zum Zitat Wong SC, Lo ES, Lee KC, et al. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004;10:1401–8.PubMedCrossRef Wong SC, Lo ES, Lee KC, et al. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004;10:1401–8.PubMedCrossRef
42.
Zurück zum Zitat Hsu HP, Shan YS, Jin YT, et al. Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J Surg Oncol. 2010;101:356–62.PubMed Hsu HP, Shan YS, Jin YT, et al. Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J Surg Oncol. 2010;101:356–62.PubMed
43.
Zurück zum Zitat Kim MA, Lee HS, Lee HE, et al. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology. 2009;54:442–51.PubMedCrossRef Kim MA, Lee HS, Lee HE, et al. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology. 2009;54:442–51.PubMedCrossRef
44.
Zurück zum Zitat Fuyuhiro Y, Yashiro M, Noda S, et al. Clinical significance of vimentin-positive gastric cancer cells. Anticancer Res. 2010;30:5239–43.PubMed Fuyuhiro Y, Yashiro M, Noda S, et al. Clinical significance of vimentin-positive gastric cancer cells. Anticancer Res. 2010;30:5239–43.PubMed
45.
Zurück zum Zitat Polette M, Gilles C, de Bentzmann S, et al. Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines. Clin Exp Metastasis. 1998;16:105–12.PubMedCrossRef Polette M, Gilles C, de Bentzmann S, et al. Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines. Clin Exp Metastasis. 1998;16:105–12.PubMedCrossRef
46.
Zurück zum Zitat Gilles C, Polette M, Mestdagt M, et al. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003;63:2658–64.PubMed Gilles C, Polette M, Mestdagt M, et al. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003;63:2658–64.PubMed
47.
Zurück zum Zitat Fang WB, Ireton RC, Zhuang G, et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci. 2008;121:358–68.PubMedCrossRef Fang WB, Ireton RC, Zhuang G, et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci. 2008;121:358–68.PubMedCrossRef
48.
Zurück zum Zitat Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther. 2006;5:228–33.PubMedCrossRef Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther. 2006;5:228–33.PubMedCrossRef
49.
Zurück zum Zitat Yuan WJ, Ge J, Chen ZK, et al. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci. 2009;54:2410–7.PubMedCrossRef Yuan WJ, Ge J, Chen ZK, et al. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci. 2009;54:2410–7.PubMedCrossRef
Metadaten
Titel
Overexpression of EphA2 correlates with epithelial–mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients
verfasst von
Futao Hou
Weijie Yuan
Jin Huang
Liyuan Qian
Zhikang Chen
Jie Ge
Shaobin Wu
Jinxiang Chen
Jixu Wang
Zihua Chen
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0127-2

Weitere Artikel der Ausgabe 4/2012

Medical Oncology 4/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.